| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab
|
Meneses-Lorente, Georgina
|
|
2017
|
79 |
6 |
p. 1239-1247
|
artikel
|
| 2 |
Adjuvant concurrent chemoradiotherapy with low-dose daily cisplatin for extrahepatic bile duct cancer
|
Kim, Sang-Won
|
|
2017
|
79 |
6 |
p. 1161-1167
|
artikel
|
| 3 |
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors
|
Haddad, Tufia
|
|
2017
|
79 |
6 |
p. 1221-1227
|
artikel
|
| 4 |
A prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer
|
Sun, Feng
|
|
2017
|
79 |
6 |
p. 1099-1107
|
artikel
|
| 5 |
Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
|
Lau, Yvonne Y.
|
|
2017
|
79 |
6 |
p. 1119-1128
|
artikel
|
| 6 |
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
|
Leng, Yun
|
|
2017
|
79 |
6 |
p. 1141-1149
|
artikel
|
| 7 |
CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis
|
Wang, Yen-Yun
|
|
2017
|
79 |
6 |
p. 1129-1140
|
artikel
|
| 8 |
Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy
|
Leamon, Christopher P.
|
|
2017
|
79 |
6 |
p. 1151-1160
|
artikel
|
| 9 |
FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
|
Xu, Y. L.
|
|
2017
|
79 |
6 |
p. 1205-1213
|
artikel
|
| 10 |
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer
|
Sadahiro, Sotaro
|
|
2017
|
79 |
6 |
p. 1077-1085
|
artikel
|
| 11 |
Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma
|
Thiery-Vuillemin, Antoine
|
|
2017
|
79 |
6 |
p. 1273-1276
|
artikel
|
| 12 |
Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
|
Zhang, Jianyuan
|
|
2017
|
79 |
6 |
p. 1087-1097
|
artikel
|
| 13 |
In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells
|
Mousavi, Elham
|
|
2017
|
79 |
6 |
p. 1195-1203
|
artikel
|
| 14 |
MITF suppression by CH5552074 inhibits cell growth in melanoma cells
|
Aida, Satoshi
|
|
2017
|
79 |
6 |
p. 1187-1193
|
artikel
|
| 15 |
Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue
|
Cohen, Ian Joseph
|
|
2017
|
79 |
6 |
p. 1057-1065
|
artikel
|
| 16 |
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese
|
Tanabe, Yuko
|
|
2017
|
79 |
6 |
p. 1179-1186
|
artikel
|
| 17 |
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations
|
Ballerini, Andrea
|
|
2017
|
79 |
6 |
p. 1267-1271
|
artikel
|
| 18 |
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study
|
Quach, Hang
|
|
2017
|
79 |
6 |
p. 1067-1076
|
artikel
|
| 19 |
Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer
|
Ikeda, Masafumi
|
|
2017
|
79 |
6 |
p. 1169-1177
|
artikel
|
| 20 |
Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
|
Aspeslagh, Sandrine
|
|
2017
|
79 |
6 |
p. 1257-1265
|
artikel
|
| 21 |
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer
|
Nishijima-Futami, Yu
|
|
2017
|
79 |
6 |
p. 1215-1220
|
artikel
|
| 22 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme
|
Bielecka-Wajdman, Anna M.
|
|
2017
|
79 |
6 |
p. 1249-1256
|
artikel
|
| 23 |
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum
|
Fujiwara, Takumi
|
|
2017
|
79 |
6 |
p. 1229-1237
|
artikel
|
| 24 |
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis
|
Chen, Xuewei
|
|
2017
|
79 |
6 |
p. 1109-1117
|
artikel
|
Tijdschrift beschrijving